10 mg · 20 mg · 30 mg · 50 mg
Retatrutide
Investigational peptide targeting GIP, GLP-1 and glucagon receptors. Studied in clinical trials on body weight and glycemic control.
For research use only
ARA-290
Synthetic peptide derived from the tissue-protective region of erythropoietin, studied in tissue-protective signaling, inflammatory pathways and nerve-related models.
- Pay by card (Stripe) or Zelle
- Ships within the U.S. with tracking
- Questions? Call or email us
Benefits under study
Clinical studies in small nerve fiber loss and type 2 diabetes.
- Small nerve fiber symptoms
- Corneal nerve fiber density
- Metabolic control in type 2 diabetes
Research overview
ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from the tissue-protective region of erythropoietin. It is designed to interact with the innate repair receptor without stimulating red blood cell production.
Preclinical research covers tissue-protective signaling, inflammatory pathways, nerve injury models and cellular stress responses. Clinical studies in Molecular Medicine evaluated it in sarcoidosis-associated small nerve fiber loss and in people with type 2 diabetes.
Supplied as a 10 mg vial for laboratory research.
Scientific references
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
Mol Med, 2013 · PMID 24136731
View on PubMedARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Mol Med, 2015 · PMID 25387363
View on PubMed
You may also need
10 mg · 20 mg
Tesamorelin
GHRH analog studied in GH/IGF-1 signaling and visceral fat, including trials in people with HIV and altered fat distribution.
100 mg
KLOW
Blend of GHK-Cu, BPC-157, TB-500 and KPV. Studies on the individual components do not evaluate the blend.